OrthoPediatrics (KIDS)
(Delayed Data from NSDQ)
$32.60 USD
-0.26 (-0.79%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $32.66 +0.06 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$32.60 USD
-0.26 (-0.79%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $32.66 +0.06 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Zacks News
Wall Street Analysts See a 32% Upside in OrthoPediatrics (KIDS): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Strength Seen in Silk Road Medical (SILK): Can Its 9.3% Jump Turn into More Strength?
by Zacks Equity Research
Silk Road Medical (SILK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -13.33% and 0.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 3.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 17.24% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of -50% and 30.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 2.08% and 2.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Abiomed (ABMD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Abiomed (ABMD) delivered earnings and revenue surprises of 15.31% and 3.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space
by Debanjana Dey
OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 47.62% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will OrthoPediatrics (KIDS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrthoPediatrics (KIDS) Moves 9.1% Higher: Will This Strength Last?
by Zacks Equity Research
OrthoPediatrics (KIDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -8.70% and 8.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrthoPediatrics (KIDS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -19.23% and -12.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 27.27% and 12.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OrthoPediatrics (KIDS) Q3 Earnings Expected to Decline
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: OrthoPediatrics (KIDS) Q2 Earnings Expected to Decline
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrthoPediatrics (KIDS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -11.11% and -3.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate OrthoPediatrics (KIDS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrthoPediatrics Announces Latest Screw System Launch in US
by Zacks Equity Research
OrthoPediatrics (KIDS) releases the latest cannulated screw system as part of its beta release to address trauma as well as other bone fixation procedures.
OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -16.00% and 3.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -5.88% and 4.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate OrthoPediatrics (KIDS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.